Fda Approval Of Olaparib Plus Abiraterone News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

North carolinaUnited statesAndrewj armstrongAshling wahnerDuke cancer institute in durhamDuke cancer instituteOnclive stateScience summitApple podcastsGoogle podcastsAmazon musicFda approval of olaparib plus abirateronePatients with brca mutated metastatic castration resistant prostate cancerDuke cancer institutePropel trial